These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32301010)

  • 41. Update on immunotherapy in melanoma.
    Green J; Ariyan C
    Surg Oncol Clin N Am; 2015 Apr; 24(2):337-46. PubMed ID: 25769716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel Targets for the Treatment of Melanoma.
    Ambrosi L; Khan S; Carvajal RD; Yang J
    Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunotherapy for patients with malignant melanoma and brain metastases].
    Simonsen LT; Schmidt AMS; Øllegaard TH; Svane IM; Bastholt L; Luczak AA; Schmidt H
    Ugeskr Laeger; 2019 Jun; 181(24):. PubMed ID: 31267950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
    Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Advances in Immunotherapy of Malignant Melanoma].
    Krajsová I
    Klin Onkol; 2017; 30(Supplementum3):40-44. PubMed ID: 29239191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunotherapy for malignant melanoma].
    Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
    Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new era in the treatment of melanoma: from biology to clinical practice.
    Márquez-Rodas I; Martín Algarra S; Avilés Izquierdo JA; Custodio Cabello S; Martín M
    Clin Transl Oncol; 2011 Nov; 13(11):787-92. PubMed ID: 22082642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
    Lee N; Zakka LR; Mihm MC; Schatton T
    Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of immunotherapy for metastatic mucosal melanoma.
    Shreders A; Joseph RW
    Immunotherapy; 2016 Jul; 8(8):843-5. PubMed ID: 27381682
    [No Abstract]   [Full Text] [Related]  

  • 56. A role of immunotherapy in metastatic malignant melanoma.
    Allen T; Gundrajakuppam L
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
    Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O
    Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melanoma as a model tumour for immuno-oncology.
    Maio M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii10-4. PubMed ID: 22918922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mucosal Melanoma: a Literature Review.
    Yde SS; Sjoegren P; Heje M; Stolle LB
    Curr Oncol Rep; 2018 Mar; 20(3):28. PubMed ID: 29569184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.